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Abstract
Background: BK virus is a polyoma virus causing renal allograft nephropathy. Reduction of immunosuppression
with the early recognition of significant BK viral loads in urine and plasma can effectively prevent BKV associated
nephropathy (BKVN), however the optimal compartment and frequency of BK viral load measurement post renal
transplantation are undetermined. Our purpose was to examine time to detection and viral loads in urine compared to
plasma, and establish viral load cut-offs associated with histological BKVN.
Methods: We performed a retrospective analysis of the BKV screening frequency and compartment(s) of 277 adult
renal transplant recipients (RTR).
Results: BKVN was histologically diagnosed in 17 (6.1 %) RTR. In cases where both urine and plasma were tested
fortnightly for 6 months (n = 53), BKV was detected in the urine 29 days earlier than plasma. Fortnightly (n = 72)
versus 3-monthly (n = 78) testing demonstrated that BKV was detected in the urine significantly earlier (median
63 versus 97 days, p = 0.001) and at a lower level (median 3.27 versus 6.71 log10 c/mL, p < 0.001) with more frequent
testing, but this difference was not evident in plasma first detection (80 versus 95 days, p = 0.536) or first positive viral
load (3.18 versus 3.30 log10 c/mL, p = 0.603). The optimum cut-off BK viral load for histological diagnosis of BKVN was 4.
10 log10 c/mL for the first positive urine, 3.79 log10 c/mL for the first positive plasma, 9.24 log10 c/mL for the peak urine,
and 4.53 log10 c/mL for the peak plasma.
Conclusions: Frequent urinary BK viral load screening for the prevention of BKVN is suggested due to its high
sensitivity and earlier detection.
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Background
BK virus (BKV) is a ubiquitous polyoma virus that
causes a clinically important pattern of renal allograft in-
jury in approximately 5 % of renal transplant recipients
(RTR). Although viral replication can occur in up to
60 % of recipients [1], in its most severe form, invasive
disease leads to tubulointerstitial nephritis and allograft
dysfunction with a significant risk of allograft failure in
15–50 % of affected individuals. Recognised risk factors
for BK virus nephropathy (BKVN) include the intensity
of immunosuppression, treatment of acute rejection,
male gender, ureteral trauma, and diabetes mellitus [2].
Strategies involving early screening and pre-emptive
management (mainly reduction in immunosuppression)
can prevent long term graft dysfunction due to invasive
disease [2]. Once BKVN is established, treatment op-
tions apart from reduction in immunosuppression are
unproven and largely untested by clinical trials. Mea-
sures for the early identification of risk in order to pre-
vent progression of viral replication and progressive
infection are therefore preferred.
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Screening for BK virus can be performed by examin-
ation for urinary decoy cells, Haufen on electron micros-
copy of the urine, or more commonly by urine or
plasma detection of virus by molecular methods. Rec-
ommendations on the suggested frequency of screening
are largely opinion based but in general suggest 1–3
monthly in the first 6 months post transplantation
followed by 3 monthly testing until 1 to 5 years post
transplantation [2–4]. Definitive evidence of BKVN re-
quires histological evidence of viral injury and exclusion
of other causes of graft dysfunction by renal biopsy. Typ-
ically, extensive tubulointerstitial nephritis with positive
immunohistochemical staining of the SV40 large T anti-
gen is noted, however disease can be focal and missed
by renal biopsy if sample size is inadequate [2]. Some
studies suggest that BKVN can be presumptively diag-
nosed when the plasma viral load exceeds 104 copies/mL
[2, 4]. However in the absence of a quantitative inter-
national standard for BK virus assays, such cut-off values
for individual assays need to be validated at an institu-
tional level.
In Western Australia, the two renal transplant services
independently introduced different screening strategies
such that the renal transplant centre at Royal Perth Hos-
pital performed fortnightly BKV screening of both urine
and plasma for the first 6 months post transplantation,
whilst Sir Charles Gairdner Hospital tested 3-monthly
urine and plasma for the first 6 months. The introduc-
tion and adherence to these strategies varied over time
within both centres. This “quasi-randomisation” by hos-
pital allows unique comparison of the performance of dif-
ferent compartments and frequencies utilised in screening
for BKVN.
Methods
We performed a retrospective cohort study of the 277
consecutive adult renal transplants performed over the
5 year period between January 2008 and December 2012
at Royal Perth and Sir Charles Gairdner Hospitals who
had at least 12 months clinical follow up. We extracted
laboratory data from the electronic pathology results
and patient clinical records and recorded the histological
diagnoses and scores assigned to renal biopsies (per-
formed for protocol or investigation of renal dysfunction),
specifically relating to the coding of acute rejection and
BKVN. We recorded all BKV plasma and urine viral load
results and screening frequency then determined the tim-
ing and level of the first positive and the peak BK viral
load for urine and plasma. Data were evaluated to 31 De-
cember 2013.
In Western Australia patients receive Basiliximab in-
duction and routine triple immunosuppression with
Tacrolimus, Mycophenolate sodium or mofetil and oral
Prednisolone. Target levels are usually 5–10 mcg/L for
Tacrolimus for the first 3 months and Prednisolone is ta-
pered to 5–10 mg daily by 3 months.
All renal histology was performed by histopathologists
trained in renal histology and reported for the purposes
of clinical management only. Histology diagnosed as
acute rejection (borderline, grade I-III), acute humoral
rejection or BKVN were coded dichotomously as biopsy-
proven acute rejection (BPAR) rejection (yes/no) and
BKVN (yes/no). All BKVN cases demonstrated positive
immunostaining against SV40. Rejection episodes diag-
nosed by biopsy were managed with an increment in ste-
roids as intravenous pulses, and for unresponsive cases
additional treatment with anti-T cell therapies were
commenced.
The four value MDRD study equation for creatinine
values standardised to creatinine reference materials was
used to calculate eGFR in mL/min per 1.73 m2 = 175 ×
SCr-1.154× Age0.203 × (0.742 if female) × (1.21 if black).
We did not apply the correction factor for “black” race
to Aboriginal and Torres Strait Islanders as there is in-
sufficient evidence it applies to this specific indigenous
group.
Molecular methods
Samples were EDTA plasma or sterile urine. Extraction,
polymerase chain reaction (PCR) and detection was per-
formed as previously described with some modifications
[5]. Briefly, 200 μL of sample was extracted with the
MagNaPure LC instrument using the Total Nucleic Acid
Isolation Kit. A 50 μL volume of elution buffer was used.
A total of 5 μL of eluted nucleic acid was added to
15 μL of PCR mix comprising 2 μL FastStart 10X Reac-
tion Mix Hybridisation probes, 2 μL MgCl2 at 25 μmol/
L, 1 μL each of forward and reverse primer at 20 μmol/
L, 0.2 μL BKV probe at 20 μmol/L and 8.8 μL of water.
PCR Amplification of the BK virus capsid protein-1 (VP-
1) gene was performed using the LightCycler 1.5 instru-
ment with 45 cycles amplification at 95°C 10 s, 60°C
20 s, 72°C 15 s. Oligonucleotide sequences used for the
BKV forward primer were 5’ GCA GCT CCC AAA
AAG CCA AA 3’, for the BK reverse primer were 5’
CTG GGT TTA GGA AGC ATT CTA 3’, and for the
BKV probe were 5’ 6FAM–ACC CGT GCA AGT GCC
AAA ACT AC–BHQ1 3’. An entire genome of Dunlop
strain BKV in a pBR322 plasmid served as a quantitative
standard of 1 × 106 copies/reaction with a crossing point
of 22 cycles. Positive and negative controls were utilised
for each PCR run. The lower and upper limits of quanti-
fication are 2.7 log10 and 9.87 log10 copies/mL.
Statistical methods
Categorical variables were compared with Fisher’s exact
test, and continuous variables by Mann Whitney U test
(of log10 results in the case of viral load measurements).
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Urine and plasma viral load association were determined
by simple linear regression and determination of Pear-
son’s correlation coefficient after log-transformation. Re-
ceiver operator characteristic analysis was performed
according to DeLong [6]. MedCalc version 12.4.0.0 was
used for statistical analysis. Statistical significance was
defined by p-value <0.05 with two-tailed tests.
Ethical considerations
The study was approved by the Human Research Ethics
Committee of Royal Perth Hospital and was conducted
according to the principles of the National Statement on
Ethical Conduct in Human Research [7].
Results
Patient characteristics
Excluded were 28 renal transplants who failed to reach
12 months follow up due to death (n = 6), graft loss (n =
8), loss to follow up (n = 14). 23 transplants had at least
one renal biopsy, none with BKVN. Baseline data of the
included 277 renal transplants with and without BKVN
with at least 12 months follow up are presented in
Table 1. Death occurred in 0 versus 20 (p = 0.621), graft
loss 1 versus 8 (p = 0.439), and loss to follow up 0 versus
2 (p = 1.000) BKV positive versus BKV negative trans-
plants respectively. BK viral load screening frequency in
the first 6 months after renal transplantation was fort-
nightly (n = 72), monthly (n = 22), 3 monthly (n = 78), 6
monthly (n = 27) and nil (n = 78).
BK nephropathy cases
BKVN was confirmed histologically in 17 (6.1 %) trans-
plants. The median time to a histological diagnosis of
BKVN was 233 days: in 4 patients virologically screened
fortnightly this was 55, 67, 136, 283 days compared with
eight patients screened every 3 months at 89, 99, 103,
170, 194, 233, 271, 324 days (p = 0.368). The time to
BKVN was 469, 920, 1113 days in the three cases with
no screening in the 6 months post transplantation,
806 days for one case screened 6 monthly, and 666 days
for one case screened monthly. Patients with BKVN had
a non-significant trend towards higher reported BPAR
and significantly reduced eGFR at 12 months (Table 1).
There were no episodes of BPAR following the diagnosis
of BK nephropathy.
Urine compared with plasma viral load screening
In the 53 cases where urine and plasma were screened
fortnightly for the first 6 months post transplantation,
BKV was detected in the urine of 32 cases and in the
plasma of 30 cases. In 27 cases BKV was detected in
both urine and plasma. In five cases BKV was only de-
tected in the urine with peak viral loads of 3.3, 3.5, 5.0,
5.4 and 6.0 log10 copies/mL (c/mL). In three cases BKV
was only detected in plasma, with peak viral loads of 3.0,
3.6, and 4.4 log10 c/mL. Median time to the first positive
urine BK viral load was shorter compared to the first
positive plasma BK viral load (61 [25–104 interquartile
range {IQR}] versus 90 [54–148 IQR] days, p = 0.066).
The time between the first positive viral load and the
peak viral load did not differ within the urine and
plasma compartments (38 [3–113 IQR] versus 41 [0–
153 IQR] days, p = 0.754). Urinary viral loads commonly
reach the upper quantifiable limit of the test (log10 9.87
c/mL) which limits the precision of this calculation.
However despite this limitation there was a significant
correlation between the peak urine and plasma viral load
of the 35 cases where both compartments were screened
fortnightly and BKV was detected in at least one com-
partment (correlation coefficient 0.53, p = 0.001, 0.24–
0.74 95 % CI, y = 3.2119 + 0.8353×; Fig. 1).
Comparison of screening frequencies
There was no significant difference in the prevalence of
BKVN or eGFR at 12 months between fortnightly versus
the 3-monthly screening strategies (Table 2). Urine viral
loads were detected earlier (Fig. 2) and at lower levels in
the fortnightly group, while first positive plasma viral
loads were similar between the two groups (Table 2).
The incidence of BKVN was 3.8 % in the 78 patients
where no virological screening was performed although
the surveillance by protocol or for cause renal biopsy
Table 1 Characteristics of renal transplants with and without BK nephropathy
Characteristic BK nephropathy (n = 17) No BK nephropathy (n = 260) p-value
Age (years) 58.3 (47.8–61.6) 51.2 (41.6–58.1) 0.113
Male 12 (70.6) 157 (60.4) 0.454
ATSIa 0 (0) 31 (11.9) 0.232
Follow up (years) 4.1 (2.1–4.9) 3.4 (2.4–4.8) 0.966
Acute Rejection 7 (41.1) 56 (21.5) 0.074
eGFR at 12 months (mLs/min) 35.6 (22.3–52.2) 48.3 (38.6–59.8) 0.014
Results are median (percentage or interquartile range)
aATSI, aboriginal or Torres Strait Islander
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was similarly high between those cases where no screen-
ing versus any screening was performed (87.2 % versus
84.9 %, p = 0.707).
Urine and plasma viral loads for predicting BK
nephropathy
Utilising only cases with a detectable viral load undergo-
ing 3 monthly or more frequent screening of the rele-
vant compartment, we found the first and peak urinary
and plasma viral loads were significantly higher in those
cases with BKVN (Table 3).
Receiver operator characteristic analysis suggested op-
timal cut-offs for BKVN of 4.10 log10 c/mL for first posi-
tive urine, 3.79 log10 c/mL for first positive plasma, 9.24
log10 c/mL for peak positive urine, 4.53 log10 c/mL for
peak positive plasma (Table 4, Fig. 3a, b, c, d).
Discussion
We examined and compared the frequency and com-
partment of BK viral load testing in relation to BKVN di-
agnosed by renal histopathology and defined potential
receiver operator characteristic derived cut-offs for diag-
nostic accuracy. In our subset of 53 cases where fort-
nightly testing of both urine and plasma were
performed, BKV was detected 29 days sooner in urine
than plasma. Therefore monitoring of urine allows the
earliest identification of viral replication, in agreement
with other studies [8, 9]. Subgroup analysis of 14 cases
by Funk et al. found BKV in the plasma became detect-
able 50 days after the urine compartment, however the
frequency of testing and time from transplant were not
recorded.8 Babel et al. recorded viremia 6 weeks after
viruria from 233 patients tested monthly for BKV in
blood and urine [9].
It was anticipated that more frequent screening (fort-
nightly versus 3-monthly) would detect BKV in the urine
earlier and at a lower viral load as shown in our study,
however we demonstrate that there was no statistical
difference in the time to first detection or the initial viral
load for the plasma compartment between the two
screening frequencies. We reason that this discrepancy
relates to BKV appearing in the plasma much later than
Fig. 1 Correlation of peak plasma and urine BK viral load (log10
copies/mL). Legend: Correlation coefficient 0.53, 0.24–0.74 95 % CI,
p = 0.001, y = 3.2119 + 0.8353×
Fig. 2 Time to first positive BK urine viral load, fortnightly vs 3-monthly
testing. Legend: Kaplan-Meier curve of time to first positive BK urine
viral load in the first 200 days post transplantation for patients tested
fortnightly (solid line) and 3-monthly (dashed line)
Table 2 Comparison of fortnightly and 3-monthly BK viral load screening strategies
Characteristic Fortnightly (n = 72) 3-monthly (n = 78) p-value
First positive urine viral load 3.27 (3.03–4.25) 6.71 (4.90–8.23) <0.001
First positive plasma viral load 3.18 (2.88–3.78) 3.30 (2.89–4.19) 0.603
Peak urinary viral load 7.96 (4.54–9.70) 7.88 (5.76–9.52) 0.911
Peak plasma viral load 3.85 (3.20–5.28) 4.23 (3.26–5.11) 0.965
Time to first positive urine viral load 63 (28–100) 97 (90–131) 0.001
Time to first positive plasma viral load 80 (52–155) 95 (73–120) 0.536
eGFR at 12 months 47.0 (34.1–57.9) 44.9 (35.8–60.0) 0.870
BK nephropathy 4 (5.55) 8 (10.26) 0.372
Results are median (interquartile range), except BK nephropathy which is number (%). Viral loads are log10 copies/mL. Viral load data represent those cases with a
detectable viral load where the compartment was used for screening
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in urine such that less advantage is found by more fre-
quent plasma screening early post transplantation. We
could not detect a difference in BKVN prevalence be-
tween these two screening frequencies although this
may be due to insufficient sample size. We cannot ex-
plain the low prevalence of BKVN demonstrated for
those transplants in whom no virological screening was
performed. Although renal biopsy was performed for a
similar percentage of these transplants, it is possible
there was less active case-finding associated with un-
measured variables in this group. We do not advocate
cessation of BK viral load screening on account of this
finding of uncertain significance.
We confirmed that our in-house BKV quantitative
assay is able to predict the risk of histologically
proven BKVN and show that the ROC analysis identi-
fies an optimal viral load cut-off for BKVN of 4.10
log10 c/mL for the first positive urine, 3.79 log10 c/
mL for first positive plasma, 9.24 log10 c/mL for peak
urine and 4.53 log10 c/mL for peak plasma. Kudose et
al. obtained similar optimal BK viral load cutoffs of
7.2 and 3.7 log10 copies/mL in urine and plasma re-
spectively for the detection of BKVN in concurrent
biopsy [10], another study identifying plasma BK viral
load of 4.1 log10 copies/mL as the best discriminator
of BKVN [11]. Therefore viral load cut-offs proposed
in the literature of 7 log10 c/mL in urine and 4 log10
c/mL in plasma are similar to our results [2, 3, 12,
13], after accounting for our difference between initial
and peak cut-offs.
However since the object of screening is to prevent
the development of BKVN, based on our data, we de-
duce that the urine must be utilised if regular screening
is performed early post transplantation to provide an ad-
vantage in earlier detection of BKV at a low viral load.
There is no advantage in regular screening of plasma be-
cause there was no significant difference found in the
time to first detection or initial viral load between fort-
nightly and 3-monthly testing. Additionally in contrast
to the urine compartment, there is little difference in ini-
tial and peak ROC derived plasma viral load cut-offs for
BKVN, suggesting the moment BKV is detected in the
plasma the patient is at imminent risk for BKVN. If only
plasma is screened, there is limited lead time for inter-
vention to prevent BKVN. Adding to these concerns of
relying on testing of the plasma compartment to screen
or presumptively diagnose BKVN is a single study show-
ing 11 of 31 patients with BKVN had plasma BK viral
loads consistently <4 log10 copies/mL [14].
Accordingly, our adopted practice is regular urine BK
viral load testing as the primary screening strategy due
to its high sensitivity and earlier detection than the
plasma compartment, with restriction of plasma testing
to patients with a urine viral load exceeding 7 log10 c/
mL. We suggest that utilising a urine first strategy pro-
vides an early warning to clinicians to take measures to
modify the risk of progressive BKV replication. We con-
firm that a plasma BK viral load greater than 4 log10 c/
mL is predictive of a risk of BK nephropathy and should
prompt diagnostic biopsy and significant modification of
immunosuppression or additional therapy according to
the clinical situation. This study validates the approach
previously proposed by Hirsch et al. [2].
The major limitation of the study relates to the reli-
ance on histopathology for the diagnosis because histo-
pathological changes occur late in the disease and
disease can be missed by biopsy due to focal involve-
ment. Biopsies were performed at the discretion of the
treating physician rather than as part of a protocol and
the decision to biopsy the patient may have been influ-
enced by the BK viral loads leading to ascertainment
bias. Due to logistical constraints, we lack information
about risk factors for the development of BKVN and the
management of presumptive or confirmed BKVN, how-
ever this was not the aim of this study. The transplants
screened 3-monthly and fortnightly were largely from
two different transplant centres, and BKV management
was not protocolised across the centres. Bias according
to centre could have potentially contributed to the out-
comes of the two groups.
As the presence of BKV antigen-specific T-cell re-
sponses are associated with control of BKV replication
[15–18], and there are scant reports of the association of
BKV genotype with BKVN [19, 20], with further study it
Table 3 First and peak urine and plasma viral loads with and
without BK nephropathy
Viral load BK nephropathy No BK nephropathy p-value
First positive urine 7.79 (5.05–9.70) 3.54 (3.10–6.70) 0.001
Peak urine 9.70 (9.70–9.70) 6.72 (4.37–9.00) <0.001
First positive plasma 4.81 (3.73–5.40) 3.05 (2.86–3.68) <0.001
Peak plasma 5.73 (5.25–6.75) 3.63 (3.01–4.53) <0.001
Viral loads are median (interquartile range) log10 copies/mL. Data represents
those transplants with a detectable viral load undergoing 3-monthly or more
frequent testing of the compartment in the first 6 months post transplantation.
BK nephropathy: urine testing (n = 11), plasma testing (n = 13). No BK
nephropathy: urine testing (n = 115), plasma testing (n = 153)
Table 4 Receiver Operator Characteristic analysis of optimal
viral load cut-offs for detecting BK nephropathy
Viral load Cutoffa Sensitivity Specificity AUCb
First positive urine 4.10 100 54 0.80
Peak urine 9.24 91 81 0.88
First positive plasma 3.79 77 81 0.85
Peak plasma 4.53 100 76 0.92
aViral loads in log10 copies/mL.
bAUC = area under the curve
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would be interesting to evaluate BKV specific T-cell im-
munity and BKV genotype for differences in cases with
low or undetectable BK viral loads, high BK viral loads
without BKVN, and those cases with BKVN.
Conclusions
In this retrospective observational study, we have not
been able to demonstrate that better clinical out-
comes are associated with more frequent BK viral
load testing or testing of a particular compartment.
However we have shown if frequent BK viral load
testing is employed early post transplantation, the ad-
vantage of earlier detection is found for urine but not
plasma testing. Additionally, the initial detection of
BKV in the plasma occurs at a level already predict-
ing a risk of BKV nephropathy. For these reasons we
suggest urine rather than plasma as the optimal com-
partment for BK viral load screening.
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